![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
Sponsored by: |
Hoffmann-La Roche |
---|---|
Information provided by: | Hoffmann-La Roche |
ClinicalTrials.gov Identifier: | NCT00717314 |
This 2 arm study will compare the efficacy and safety of switching to CellCept combined with different regimens of reduced calcineurin inhibitors (CNI) in patients with liver transplants. Patients currently receiving CNI treatment will be randomized into one of 2 groups to receive either 1) CellCept 2.0g/day po bid + 50% reduction of CNI from baseline or 2) CellCept 2.0g/day po bid + >=75% reduction of CNI from baseline. The anticipated time on study treatment is 1 year, and the target sample size is <100 individuals.
Condition | Intervention | Phase |
---|---|---|
Liver Transplantation |
Drug: mycophenolate mofetil [CellCept] Drug: CNI |
Phase IV |
Study Type: | Interventional |
Study Design: | Open Label, Parallel Assignment, Randomized, Safety/Efficacy Study, Treatment |
Official Title: | A Randomized, Open Label Study Comparing the Effect of CellCept Combined With 2 Regimens of Reduced Calcineurin Inhibitors on Kidney Function in Liver Transplant Patients |
Estimated Enrollment: | 90 |
Study Start Date: | October 2008 |
Estimated Study Completion Date: | May 2010 |
Arms | Assigned Interventions |
---|---|
1: Experimental |
Drug: mycophenolate mofetil [CellCept]
2.0g/day po bid
Drug: CNI
50% reduction from baseline
|
2: Experimental |
Drug: mycophenolate mofetil [CellCept]
2.0g/day po bid
Drug: CNI
>=75% reduction from baseline
|
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Please reference Study ID Number: ML21241 | 973-235-5000 | |
Contact: or | 800-526-6367 (FOR US ONLY) |
China | |
Recruiting | |
SHANGHAI, China, 200003 | |
Recruiting | |
SHANGHAI, China, 200080 | |
Recruiting | |
CHENGDU, China, 610041 | |
Recruiting | |
Changsha, China, 410013 | |
Recruiting | |
NANJING, China, 210029 | |
Recruiting | |
GUANGZHOU, China, 510080 | |
Completed | |
BEIJING,, China, 100039 | |
Recruiting | |
Xian City, China, 710032 | |
Recruiting | |
BEIJING, China, 100054 | |
Recruiting | |
Chongqing, China, 400038 |
Study Director: | Clinical Trials | Hoffmann-La Roche, +1 973 235 5000 |
Responsible Party: | Hoffmann-La Roche ( Clinical Trials, Study Director ) |
Study ID Numbers: | ML21241 |
Study First Received: | July 16, 2008 |
Last Updated: | February 17, 2009 |
ClinicalTrials.gov Identifier: | NCT00717314 History of Changes |
Health Authority: | China: State Food and Drug Administration |
Anti-Bacterial Agents Mycophenolic Acid Mycophenolate mofetil Immunosuppressive Agents |
Molecular Mechanisms of Pharmacological Action Immunologic Factors Antineoplastic Agents Therapeutic Uses Physiological Effects of Drugs Mycophenolic Acid |
Mycophenolate mofetil Enzyme Inhibitors Antibiotics, Antineoplastic Immunosuppressive Agents Pharmacologic Actions |